Recently, it was recognized that a group of HER2-low expressing tumours responded to trastuzumab deruxtecan (T-DXd) therapy; an antibody drug conjugate (ADC) that affects cancer cells expressing small quantities of HER2 protein and those surrounding them via a by-stander effect. Here, ERBB2 is linked to neoplasm.